^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EMT gene signature

    1year
    Loss of the predicted cell adhesion molecule MPZL3 promotes EMT and chemoresistance in ovarian cancer. (PubMed, bioRxiv)
    This was associated with increased resistance to Cisplatin and Olaparib and reduced DNA damage and apoptosis in response to these agents. These data demonstrate for the first time that MPZL3 acts as an adhesion molecule and that MPZL3 loss results in EMT, decreased proliferation, and drug resistance in ovarian cancer. Our study suggests that decreased MPZL3 expression is a phenotype of ovarian cancer tumor progression and metastasis and may contribute to treatment failure in advanced-stage patients.
    Journal • PARP Biomarker
    |
    MPZL3 (Myelin Protein Zero Like 3) • VIM (Vimentin) • ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    |
    Lynparza (olaparib) • cisplatin
    over1year
    Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinoma. (PubMed, Breast Cancer Res)
    Our findings provide insights into the characteristics and transcriptional regulators of spontaneous EMT in primary non-spindled carcinoma.
    Journal
    |
    VIM (Vimentin) • TWIST1 (Twist Family BHLH Transcription Factor 1) • ITK (IL2 Inducible T Cell Kinase) • SNAI1 (Snail Family Transcriptional Repressor 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)
    |
    EMT gene signature • VIM expression • ZEB1 expression
    almost2years
    A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction. (PubMed, J Pathol)
    Both gene signature and E-cadherin alterations could be reversed by the proteasomal inhibitor MG132..
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CDH1 (Cadherin 1) • SOX10 (SRY-Box 10) • SERPINE1 (Serpin Family E Member 1) • ITK (IL2 Inducible T Cell Kinase)
    |
    EGFR expression • EMT gene signature
    |
    MG132
    2years
    Comprehensive analyses and experimental verification of NETs and an EMT gene signature for prognostic prediction, immunotherapy, and chemotherapy in pancreatic adenocarcinoma. (PubMed, Environ Toxicol)
    Transwell assays and western blotting showed that cell invasion and EMT induction were significantly reduced after DCBLD2 knockdown. Collectively, we constructed a prognosis model based on a NET and EMT gene signature, providing a valuable perspective for the prognostic evaluation and management of PAAD patient.
    Journal • Gene Signature • IO biomarker
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    2years
    Attenuating epithelial-to-mesenchymal transition in cancer through angiopoietin-like 4 inhibition in a 3D tumor microenvironment model. (PubMed, Adv Healthc Mater)
    Suppression of Angptl4 using antisense oligonucleotides or anti-cAngptl4 antibodies led to a dose-dependent abolishment of EMT-mediated chemoresistance and tumor self-organization in 3D, ultimately resulting in diminished metastatic potential and stunted growth of tumor xenografts. Our unique programmable 3D cancer cultures simulated stiffness levels in the tumor microenvironment and unveiled Angptl4 as a promising therapeutic target to inhibit EMT and impede cancer progression.
    Journal
    |
    ITK (IL2 Inducible T Cell Kinase) • ANGPTL4 (Angiopoietin Like 4)
    |
    EMT gene signature
    over2years
    Systematic establishment and verification of an epithelial-mesenchymal transition gene signature for predicting prognosis of oral squamous cell carcinoma. (PubMed, Front Genet)
    After validation, AREG, COL5A3, DKK1, GAS1, GPX7 and PLOD2 were distinctly upregulated and SFRP1 was downregulated in OSCC than normal tissues. Our data identified and verified a robust EMT gene signature in OSCC, which provided a novel clinical tool for predicting prognosis and several targets against OSCC therapy.
    Journal • Gene Signature
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • GAS1 (Growth Arrest Specific 1) • ITK (IL2 Inducible T Cell Kinase) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • SFRP1 (Secreted frizzled related protein 1) • GPX7 (Glutathione Peroxidase 7)
    |
    EMT gene signature
    over2years
    Epithelial-to-Mesenchymal Transition Gene Signature in Circulating Melanoma Cells: Biological and Clinical Relevance. (PubMed, Int J Mol Sci)
    In conclusion, We established a reliable qRT-PCR protocol with high sensitivity and specificity to characterize the gene expression of isolated CMCs. To our knowledge, this is the first evidence demonstrating the impact of immune or targeted therapies on EMT hallmark gene expressions in CMCs from advanced melanoma patients.
    Journal • Gene Signature
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    over2years
    Epithelial-to-mesenchymal transition is a major contributor to intratumor heterogeneity in lymph node breast cancer metastasis (EACR 2023)
    Further, the presence of cancer cell clusters located between the epithelial and mesenchymal cluster might point towards cells in an intermediated hybrid state. ConclusionScRNA-seq can be utilized to visualize intratumor heterogeneity and to identify the underlying molecular mechanism affected by metastasis to the lymph nodes in breast cancer.
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    almost3years
    Prognostic Value of EMT Gene Signature in Malignant Mesothelioma. (PubMed, Int J Mol Sci)
    In conclusion, we observed that the expression of a panel of MESO EMT genes was associated with hypermethylation of epigenetic genes and loss of expression of CDKN2A and CDKN2B. Expression of MESO EMT genes was associated with downregulation of the type I and type II IFN response, loss of cytotoxicity and NK cell activity, and upregulation of specific immune checkpoints, as well as upregulation of the TGF-β1/TGFBR1 pathway.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PD-L2 (Programmed Cell Death 1 Ligand 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • SERPINH1 (Serpin family H member 1) • ACTA2 (Actin Alpha 2 Smooth Muscle) • TGFB1 (Transforming Growth Factor Beta 1) • IFNA1 (Interferon Alpha 1) • ITK (IL2 Inducible T Cell Kinase) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • COL5A2 (Collagen Type V Alpha 2 Chain) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • LGALS9 (Galectin 9) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    EMT gene signature • CDKN2B expression